Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 2 of 2 for:    als atlis

Longitudinal Study of Outcomes Measures in ALS Trials

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Massachusetts General Hospital
ALS Association
Information provided by (Responsible Party):
Patricia L. Andres, Massachusetts General Hospital Identifier:
First received: July 10, 2013
Last updated: July 21, 2014
Last verified: July 2014

A new strength measurement device called Accurate Test of Limb Isometric Strength (ATLIS) was developed to precisely and conveniently measure static limb strength in patients with ALS. The investigators will compare ATLIS data with data from two commonly used ALS outcomes measures, the ALS Functional Rating Scale-Revised (ALSFRS-R) and slow vital capacity (SVC) in a prospective, longitudinal study. All three outcomes measures will be performed on 100 subjects collected preferably at bi-monthly clinic visits during the study period.

Amyotrophic Lateral Sclerosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Longitudinal Study Comparing the Responsiveness of Outcomes Measures in ALS Trials

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Change in Accurate Test of Limb Isometric Strength (ATLIS) between each visit [ Time Frame: every 1 to 4 months for up to two years ] [ Designated as safety issue: No ]
    ATLIS measures isometric strength in 12 muscle groups in the arms and legs. The subject is tested seated in a specially designed chairs with adjustable uprights. The subject's limb is placed in a standard position and maximal force is exerted on the wireless load cell fixed to the upright. Strength data is digitally captured and expressed as a percentage of expected normal.

Secondary Outcome Measures:
  • Change in ALS Functional Rating Scale - Revised (ALSFRS-R) between each visit [ Time Frame: every 1 to 4 months for up to 2 years ] [ Designated as safety issue: No ]
    This questionnaire consists of 12 questions about the subject's ability to function in certain daily activities. Questions are asked in an interview format.

  • Change in Slow Vital Capacity (SVC) between each visit [ Time Frame: Every 1 to 4 months for up to two years ] [ Designated as safety issue: No ]
    SVC measures the amount of air you can exhale following a deep breath. For this test, we will ask you to hold a mouthpiece in your mouth, breathe in deeply, and breathe out as much air as you can, up to 5 times.

Estimated Enrollment: 100
Study Start Date: July 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Detailed Description:

Four sites will participate in data collection for this study and will enroll approximately 20-30 subjects per site. Subjects will be tested every 1 to 4 months for up to two years. Subjects will be tested at each visit using ATLIS, ALSFRS-R questionnaire and slow vital capacity testing.

Inclusion criteria:

  • Subjects 18 years or older diagnosed with clinically possible, laboratory supported probable, probable or clinically definite ALS according to the World Federation of Neurology Revised El Escorial Criteria.
  • Capable of providing informed consent and complying with trial procedures.

Exclusion criteria:

- Patients, judged by the site clinical investigator to have medical conditions that may limit their ability to safely exert maximal force using the muscles in their arms and legs will be excluded from this study (e.g. unstable hypertension, significant cardiac disease, significant musculoskeletal disorders, or other medical conditions).


Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Adults with ALS


Inclusion Criteria:

  • 18 years or older
  • clinically possible, laboartory supported probable, probable or clinically definite ALS according to El Escorial Criteria
  • capable of providing informed consent

Exclusion Criteria:

  • persons with medical conditions that would limit their ability to safely exert maximal force using muscles in their arms and legs (e.g. unstable cardiac, musculoskeletal, or other medical conditions)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01911130

Contact: Patricia L. Andres, DPT, MS 617-724-8995

United States, California
Cedars-Sinai Medical Center Recruiting
Los Angeles, California, United States, 90048
Contact: Peggy Allred, DPT    424-315-2694   
Principal Investigator: Peggy Allred, DPT         
United States, Kentucky
University of Kentucky Recruiting
Lexington, Kentucky, United States, 40536
Contact: Tony English, PHD, PT    859-218-0834   
Contact: Mary Proffitt    859 218-0519   
Principal Investigator: Tony English, PhD, PT         
Sub-Investigator: Edward Kasarskis, MD         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Christina Dheel    617-643-6252   
Principal Investigator: James Berry, MD, MPH         
United States, Missouri
Washington University Recruiting
St. Louis, Missouri, United States, 63110
Contact: Catherine Siener, PT, MHS    314-362-8651   
Principal Investigator: Julaine Florence, DPT         
United States, Pennsylvania
Hershey Medical Center Recruiting
Hershey, Pennsylvania, United States, 17033
Contact: Beth Stephens, M.A., CCRC    717-531-0003 ext 283395   
Principal Investigator: Zachary Simmons, MD         
Sponsors and Collaborators
Massachusetts General Hospital
ALS Association
Principal Investigator: Patricia L. Andres, DPT, MS Massachusetts General Hospital
  More Information

No publications provided

Responsible Party: Patricia L. Andres, Senior Research Scientist, Massachusetts General Hospital Identifier: NCT01911130     History of Changes
Other Study ID Numbers: 2013P000702
Study First Received: July 10, 2013
Last Updated: July 21, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
outcomes measures
strength measurement
disease progression

Additional relevant MeSH terms:
Amyotrophic Lateral Sclerosis
Central Nervous System Diseases
Metabolic Diseases
Motor Neuron Disease
Nervous System Diseases
Neurodegenerative Diseases
Neuromuscular Diseases
Proteostasis Deficiencies
Spinal Cord Diseases
TDP-43 Proteinopathies processed this record on November 20, 2014